Free Access
Med Sci (Paris)
Volume 33, Number 12, Décembre 2017
Page(s) 1121 - 1123
Section Forum
Published online 20 December 2017
  1. Jordan B. Immunothérapie « CAR-T » : une autorisation qui fait date. Med Sci (Paris) 2017 ; 33 : 1003–1006. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol 2017 ; 14 : 381–390. [PubMed] [Google Scholar]
  3. Zafar SY. Financial toxicity of cancer care: It’s time to intervene. J Natl Cancer Inst 2015; 108 : djv370. [CrossRef] [PubMed] [Google Scholar]
  4. [Google Scholar]
  5. [Google Scholar]
  6. [Google Scholar]
  7. [Google Scholar]
  8. [Google Scholar]
  9. Ward, A. Expensive drugs cost lives, says report. Financial Times, Feb. 19, 2015. [Google Scholar]
  10. Courtney D, Huseyin N, Evrim G, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European medicines agency: retrospective cohort study of drug approvals 2009–13. BMJ 2017 ; 359 : j4530. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.